designer491
Bellicum Pharmaceuticals (OTCPK:BLCM) said it has completed the sale of substantially all of its assets to the University of Texas MD Anderson Cancer Center and will proceed with dissolving the company.
As per their asset purchase agreement, MD Anderson acquired the assets and assumed certain liabilities for a purchase price equal to $8.1M in cash, according to an SEC filing made late Wednesday.
Bellicum added that its shareholders have voted to proceed with the liquidation and dissolution of the company.
